微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: One of the most consequential year for cancer treatment, ever
RSS 官方收录 · 可信分层展示
关键摘要
2026年默沙东与ModernamRNA癌症疗法临床成功，或成抗癌史上最重要一年
- 默沙东与Moderna个性化mRNA癌症疗法晚期黑色素瘤临床试验成功
- 今年早些时候Revolution Medicines的KRAS靶向药亦获突破
- 2026年被评价为癌症治疗史上最具里程碑意义的年份之一
AI 摘要 · 来源可核验
正文提要
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Twenty-four hours later, my brain is still whirling over yesterday’s stunning news from Merck and Moderna about the success of their personalized mRNA cancer therapy in a melanoma late-stage clinical trial.
I posted this on X yesterday but it’s worth repeating here: Between this spring’s Revolution Medicines success with a KRAS-targeted drug and now Merck and Moderna’s success with an mRNA neoantigen vaccine, 2026 will go down as one of the most consequential years in cancer treatment, ever.